BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

28 May 2021 14:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 May 2021 16:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

14 May 2021 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update

06 May 2021 07:30:01 By Nasdaq GlobeNewswire

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

13 Apr 2021 07:45:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases

13 Apr 2021 07:42:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers

13 Apr 2021 07:40:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases

13 Apr 2021 07:37:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

13 Apr 2021 07:35:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research

13 Apr 2021 07:32:00 By Nasdaq GlobeNewswire